Affinity Asset Advisors’s Radiopharm Theranostics RADX Stock Holding History

Affinity Asset Advisors’s Portfolio RADX Stock Details RADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-35,635	Closed	-$166K	–	115
2025 Q2	$166K	Sell	35,635 -28,965	-45%	-$130K	0.02%	85
2025 Q1	$311K	Sell	64,600 -91,571	-59%	-$476K	0.03%	88
2024 Q4	$684K	Buy	+156,171	New	+$1.03M	0.09%	72

Other funds holding RADX

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Regal Partners Sydney, NSW, Australia $1.84B AUM 54.78% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Affinity Asset Advisors's RADX Position: Q3 2025 in Review

Affinity Asset Advisors sold out of Radiopharm Theranostics (RADX) in Q3 2025, closing a stake of 35,635 shares — an estimated $166K sold.

Affinity Asset Advisors first reported a position in RADX in Q4 2024 and held it in 3 quarters. The position peaked at $684K in Q4 2024. 4 funds tracked by Wall St. Rank hold RADX as of Q3 2025.

Affinity Asset Advisors reported no remaining Radiopharm Theranostics position as of Q3 2025 after selling out during the quarter.
Affinity Asset Advisors sold 35,635 Radiopharm Theranostics shares in Q3 2025, an estimated $166K.
Affinity Asset Advisors first reported a position in Radiopharm Theranostics in Q4 2024 and held it in 3 quarters.
Affinity Asset Advisors's Radiopharm Theranostics position peaked at $684K in Q4 2024.
4 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q3 2025.

Based on Affinity Asset Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.